tbuckley/cabot-search huggingface dataset:
Healthy Behaviors Potentially Due to Calorie Restriction
Authors: Fatih Tufan, Ozlem Soyluk, Mehmet Akif Karan
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
HLA-DPA1 Polymorphism Is a Risk Factor for Graft-Versus-Host Disease Following Unrelated Hematopoietic Stem Cell Transplantation (HSCT)
Authors: Nina Lauterbach, Christien Voorter, Lisa Rybicki, Lotte Wieten, Ronald Sobecks, Matt Kalaycio, Marcel Tilanus, Medhat Askar
Journal: Blood (2012)
The Use of Public Health Evidence in <i>Whole Woman’s Health v Hellerstedt</i>
Authors: Daniel Grossman
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
BACH2 Is Required for Pre-B Cell Receptor Checkpoint Control and p53-Dependent Tumor Surveillance
Authors: Srividya Swaminathan, Huining Kang, Richard C. Harvey, Chuanxin Huang, Maike Buchner, Zhengshan Chen, Huimin Geng, Andrew Hall, Kazuhiko Igarashi, William L. Carroll, Cheryl L. Willman, Ari Melnick, Markus Muschen
Journal: Blood (2012)
AB0276 Psychological Status Is Associated with Health Related Quality of Life in Patients with Rheumatoid Arthritis
Authors: K. Baccouche, L. Mani, S. Belghali, N. Elamri, Z. Alaya, H. Zeglaoui, E. Bouajina
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rheumatoid arthritis (RA) as one of the most common autoimmune diseases is known to be one of the leading causes of disability. <h3>Objectives</h3> This study aimed to investigate the relationship between psychological disorders (depression, anxiety and insomnia) and quality of life in patients with rheumatoid arthritis patients. <h3>Methods</h3> A total of 50 patients were included with the diagnosis of rheumatoid arthritis meeting ACR 1987 criteria, in a prospective study. In a questionnaire, the characteristics of the disease and sociodemographic patient were collected. Also psychiatric assessment was done using the insomnia severity index score (ISI) and the Hospital Anxiety and Depression scale (HAD). In addition, patients answered a Health Assessment Questionnaire (HAQ) to assess their functional capacity and the SF-12 to evaluate the quality of life. <h3>Results</h3> The female was found in 80%, the average age was 52,8 years. The average duration of disease progression was 8,79 years (0,5–30). The mean value of the DAS 28 was 5,03 [1.7 to 7.9]. Extra-articular manifestations were reported in 72% of patients: secondary Sjögrens syndrome in 54%, osteoporosis in 42%, pulmonary fibrosis in 12%. 80% of patients received methotrexate and 38% of patients were treated with biotheraby. Radiological destruction was observed in 96% of cases. Joint deformities were reported in 56% of cases. The most prevalent comorbidities in this population were anemia (28%), hypertension (18%), and diabetis (18%). On the psychological level, 12% of patients had an anxiety, 6% had depression. According to the ISI, 34% of patients had Subthreshold insomnia, 40% had moderate insomnia and 6% had severe insomnia. The mean value of the HAQ was 1.49 (0.2–3). A significant positive correlation was found between the disease activity and the presence of insomnia (p=0.019), the presence of depression (p=0.009) and anxiety (p=0.049). Also, we found a significant positive correlation between the HAQ and depression (p=0,003). The mean value of the physical health was 40.51 (16–59.2) and for the mental health was 48.13 (26–60). <h3>Conclusions</h3> Psychiatric illness is a relatively common disorder in patients with RA, it affects their quality of life. The treatment of those patients must consider psychiatric disorders, as part of a global approach. <h3>Disclosure of Interest</h3> None declared
Development and Evolution of a Hierarchical Clinical Composite End Point for the Evaluation of Drugs and Devices for Acute and Chronic Heart Failure
Authors: Milton Packer
Journal: Circulation (2016)

Traditional approaches to the assessment of new treatments for heart failure have generally evaluated individual components of the syndrome at fixed points in time or have relied on surrogate physiological measures that are poorly correlated with the clinical status of patients. Conventional time-to-event trials that focus on morbidity and mortality represent an important methodological advance, but they generally assign undue weight to clinical events of less importance and are insensitive to difference in functional capacity among individuals who do not experience a clinical event during follow-up. Twenty years ago, a hierarchical clinical composite was developed to address these limitations; it aims to assess the clinical course of patients as a physician would in practice by combining a symptomatic assessment of the patient at each visit with an evaluation of the clinical stability of the patient between visits. The composite does not generate a numeric score by summing arbitrarily assigned weights to certain symptoms or events; instead, the composite ranks relevant measures and outcomes according to clinical priority. In doing so, the clinical composite minimizes the biases created by noncompleting patients in the assessment of symptoms or exercise tolerance while expanding the range of patients who contribute to the treatment difference in a typical morbidity and mortality trial. When applied appropriately, the hierarchical clinical composite end point has reliably distinguished effective from ineffective treatments. The composite may have particular advantages in the evaluation of new devices and transcatheter interventions in chronic heart failure and of new drugs for acute heart failure. Recent modifications enhance its discriminant characteristics and its ability to accurately assess the efficacy of novel interventions for heart failure.
Lenalidomide (Revlimid®) Enhances Monoclonal Antibody-Associated Anti-Tumor Activity Against Rituximab-Sensitive and Rituximab-Resistant B-Cell Lymphoma Cell Lines.
Authors: Nishitha Reddy, Raymond Cruz, Francisco Hernandez-Ilizaliturri, Joy Knight, Myron S. Czuczman
Journal: Blood (2006)
Preliminary Results of An Ongoing Phase I Trial of Oral Belinostat a Novel Histone Deacetylase Inhibitor in Patients with Lymphoid Malignancies,
Authors: Jasmine M. Zain, Francine M. Foss, Catherine S. Diefenbach, Daniel Petrylak, Ameet Narwal, Ellen Neylon, Poul Knoblauch, Owen A. O'Connor
Journal: Blood (2011)
C/EBPα-Induced Microrna-30c Directly Targets Notch1 During Granulopoiesis and Is Repressed in Acute Myeloid Leukemia
Authors: Christiane Katzerke, Vikas Madan, Dennis Gerloff, Daniela Braeuer-Hartmann, Jens-Uwe Hartmann, Alexander Arthur Wurm, Carsten Mueller-Tidow, Susanne Schnittger, Daniel G. Tenen, Dietger Niederwieser, Gerhard Behre
Journal: Blood (2012)
Access to Care, Race and Education Are Key Determinants of Erythropoietin Stimulating Agent (ESA) Use In Myelodysplastic Syndromes (MDS).
Authors: Amy J. Davidoff, Sheila Weiss Smith, Maria R Baer, Xuehua Ke, Jason M Bierenbaum, Franklin Hendrick, Diane L. McNally, Steven D. Gore
Journal: Blood (2010)
GPIbα As a Selective Bidirectional Modulator Of α-Thrombin Prothrombotic Functions Influencing Fibrin Deposition and PAR-Dependent Platelet Activation
Authors: Alessandro Zarpellon, Antonella Zampolli, Patrizia Marchese, James R. Roberts, Grazia Loredana Mendolicchio, Zaverio M Ruggeri
Journal: Blood (2013)
Molecular alterations in bone marrow mesenchymal stromal cells derived from acute myeloid leukemia patients
Authors: E K von der Heide, M Neumann, S Vosberg, A R James, M P Schroeder, J Ortiz-Tanchez, K Isaakidis, C Schlee, M Luther, K Jöhrens, I Anagnostopoulos, L H Mochmann, D Nowak, W K Hofmann, P A Greif, C D Baldus
Journal: Leukemia (2016)
Phase II Study of Denileukin Diftitox (ONTAK®) in Patients with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (B-NHL) and Poor Bone Marrow Reserve.
Authors: Myron S. Czuczman, Lauren Pinter-Brown, Mary Jo Lechowicz, Nancy Bartlett, Hillard Lazarus, John Lister, Andre Goy, Stephen Kahanic, Peter Rosen, Mark Acosta
Journal: Blood (2006)
FRI0369 Pattern of Clinical Presentation and Disease Severity in Patients with Polymyalgia Rheumatica
Authors: D. Camellino, A. Sobrero, V. Tomatis, S. Paolino, M. Cutolo, M.A. Cimmino
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Polymyalgia rheumatica (PMR) is an inflammatory disorder of the elderly characterized by girdle pain and stiffness, constitutional symptoms and elevation of inflammatory indexes. In its classical form, the shoulder girdle is affected, associated or not with pelvic and spinal pain. The latter two locations can occasionally precede shoulder involvement. It is not known if the pattern of clinical presentation is related to disease severity at onset. <h3>Objectives</h3> In this study, disease severity of PMR has been correlated with clinical characteristics at presentation. <h3>Methods</h3> 394 patients (251 women, median age 73 yrs, range 47–92 yrs) with PMR diagnosed according to Bird9s criteria, visited between 1990 and 2014 by the same clinician were studied. Clinical features recorded at disease presentation included initial involvement of: i) the shoulder girdle; ii) the pelvic girdle; iii) the column; iv) two or more of the previous locations; v) presence of giant cell arteritis (GCA); vi) acute onset, defined as completion of full symptoms and signs in ≤72h; or vii) peripheral arthritis. Disease severity of PMR was evaluated by considering: i) weight loss; ii) fever; iii) morning stiffness (MS); iv) ESR; v) CRP; and vi) initial dose of prednisone. <h3>Results</h3> Acute onset and classical involvement of the shoulder girdle were not associated with our indicators of PMR severity. By contrast, onset in the pelvic girdle (p=0.002), simultaneous onset in multiple locations (p=0.006), peripheral arthritis (p=0.045) and GCA (p=0.0004) were associated with a higher initial dose of prednisone; multiple locations onset correlated also with MS (p=0.044). <h3>Conclusions</h3> The presentation with multiple locations, including column and pelvic girdle, peripheral arthritis, and GCA resulted in a more severe onset at least in the perception of the clinician who used a higher initial dose of prednisone. Clinicians should consider the pattern of disease presentation when evaluating the burden of PMR. <h3>Disclosure of Interest</h3> None declared
AB0336 Anti-Atherosclerotic Effects of Biologic Agents, Tocilizumab and Etanercept, in Rheumatoid Arthritis Patients
Authors: Y. Suzuki, Y. Mitsuke, N. Ootsuki, H. Tsutani
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Epidemic studies have shown that endothelial dysfunction and accelerated atherosclerosis lead to increased cardiovascular morbidity and mortality in patients with rheumatoid arthritis (RA). Cardio ankle vascular index (CAVI) measures arterial stiffness independent of blood pressure and it is superior to brachial ankle pulse wave velocity as an index of arterial stiffness. The aim of our study was to examine inhibitory effects on atherosclerosis of RA patients by biologic agents. <h3>Objectives</h3> We studied 36 RA patients with moderate or more disease activity as defined by the European League Against Rheumatism (EULAR) disease activity score (DAS28-ESR) in spite of MTX treatment. <h3>Methods</h3> We measured their CAVI before and after treatment with biologic agents (tocilizumab (TCZ) plus methotrexate (MTX)(n=11), etanercept (ETN) plus MTX (n=12), or MTX alone (n=13)) for one year. <h3>Results</h3> Each groups of characteristics (DAS 28, CRP, age, gender, disease duration) at baseline are no significantly different. Treatment with TCZ (9.62±1.56 and 9.05±1.42%, P&lt;0.05), ETN (9.72±1.68 and 9.18±1.34%, P&lt;0.05), but not MTX (9.88±1.63 and 9.79±1.87%; P=0.77) attenuated the CAVI significantly from baseline to 1 year follow-up. <h3>Conclusions</h3> TCZ and ETN but not MTX therapy may have a beneficial effect on preventing the progression of subclinical atherosclerosis and arterial stiffness. It remains unknown whether this effect is specific to TNF-alpha antagonists or relates to better control of inflammation irrespective of the disease modification strategy by which this is achieved. <h3>Disclosure of Interest</h3> None declared
OP0265 Fever of Unknown Origin (FUO) and Inflammation of Unknown Origin (IUO): Is 18F-FDG-PET/CT A Useful First Line Diagnostic Strategy?:
Authors: V. Schoenau, K. Vogel, M. Engelbrecht, D. Schmidt, T. Kuwert, B. Manger, G. Schett
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Fever of unknown origin (FUO) and inflammation of unknown origin (IUO) are rare but diagnostically challenging clinical problems. Because of the abundance of differential diagnoses, a generally accepted diagnostic guideline has not yet been established. Besides a thorough medical history, physical examination, and laboratory testing, imaging techniques are important tools in the diagnostic workup of FUO and IUO. In the last few years, <sup>18</sup>F-FDG-PET/CT has been found to be a suitable diagnostic tool for FUO/IUO, as it is able to detect inflammatory and malignant processes with a high spatial resolution. <h3>Objectives</h3> The present study is carried out at to quantify the utility of <sup>18</sup>F-FDG-PET/CT for the diagnosis of FUO and IUO. The study, moreover, evaluates special clinical markers, that increase the possibility of diagnosing FUO or IUO with a <sup>18</sup>F-FDG-PET/CT. <h3>Methods</h3> All patients presenting with FUO or IUO at the University Clinic of Erlangen between 2007 and 2015 were clinically documented and subjected to <sup>18</sup>F-FDG-PET/CT scanning. <sup>18</sup>F-FDG-PET/CT scans were considered positive when a focal uptake of the tracer was detected additionally to the standard areas of physiological tracer uptake. <sup>18</sup>F-FDG-PET/CT results were compared to the final diagnosis and classified as helpful or non-helpful in establishing the final diagnosis. Multivariate logistic regression was used to identify clinical parameters that correlated with a helpful <sup>18</sup>F-FDG-PET/CT in patients with and without FUO as well as in patients with and without IUO. <h3>Results</h3> Of the 240 patients enrolled 72 presented with FUO, 142 with IUO and 26 did not fulfill FUO or IUO criteria. 235 patients were included in the multivariate logistic regression model. Final diagnosis was established in 190 patients (79.2%). In 136 (56.7% of all patients and 71.6% of the patients with a diagnosis), the <sup>18</sup>F-FDG-PET/CT was helpful in finding the diagnosis. The chance was higher in patients without fever (p=0.003), those aged &gt;50 years (p=0.002; p=0.005, respectively) and those with a CRP level &gt;30 mg/dl (p=0.003; p=0.008, respectively). <h3>Conclusions</h3> Our study shows that if the standard diagnostic tests (laboratory, chest x-ray and abdominal ultrasound) did not identify the cause of FUO/IUO, <sup>18</sup>F-FDG-PET/CT scanning should be applied in the early stage of the diagnostic process. An early use of an <sup>18</sup>F-FDG-PET/CT is especially helpful to establish a final diagnosis in patients with an elevated C-reactive protein and age over 50 years. <h3>Disclosure of Interest</h3> None declared
A Myeloablative Regimen Incorporating Radiolabeled Anti-CD45 (BC8) Antibody Followed by Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Advanced Acute Myeloid Leukemia (AML).
Authors: Eneida R. Nemecek, John M. Pagel, Joseph G. Rajendran, Darrell R. Fisher, Frederick R. Appelbaum, Oliver W. Press, Dana C. Matthews
Journal: Blood (2004)
FRI0237 Tocilizumab Impact on Kinetics of Treatment Target Parameters in Sysemic Nephrotic Type AA-Amyloidosis, Secondary To RA
Authors: A. Alexeeva, Y. Muraviev, S. Radenska-Lopovok, E. Aleksandrova, L. Kashnikova
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Systemic AA-amyloidosis is a severe complication of RA occurring due to upregulated production of serum amyloid A (SAA), induced predominantly by IL-6. <h3>Objectives</h3> To assess Tocilizumab (humanized monoclonal antibody to IL-6 receptors) impact on kinetics of treatment target parameters in sysemic nephrotic type AA-amyloidosis, secondary to RA. <h3>Methods</h3> DAS28, SAA levels, CRP, ESR, 24-hour proteinuria, glomerular filtration (GFR), and gistomorphologic examination of biopsy samples were monitored in all participants to the study in addition to the standard clinical and lab parameters. Statistical processing covered the number of participating subjects, arithmetic mean (AM), standard deviation from AM (δ). Difefferces were considered statistically significant with <i>p</i> values &lt;0,05. Student9s <i>t</i>-test was used. Data was processed with Statistica 7.0 for Windows ("StatSoft Inc.") software. <h3>Results</h3> The study included 10 pts (mean age 52±9,1 y.) with systemic AA amiloidosis and morphologically verified nephrotic syndrome (biosy samples of duodenal mucous), secondary to RA, meeting ACR 1987 criteria (average disease duration - 17,1±8,9 y). All poor responders to DMARDs, NSAIDs and GCs at a stable dose for at minimum 6 preceding mo (peroral &lt;10 mg/day prednisolone or its equivalent) were administered Tocilizumab i/v by drop infusions each 4 weeks at 8 mg/kg during total 12 mo. After 12 mo of therapy significant decrease was documented for mean SAA (from 46,7±28,1 mg/mL to 14,7±24,3 mg/mL; <i>p</i>=0,03), DAS28 score (from 5,5±1,4 to 3,3±1,15; <i>p</i>=0,003), 24-hour proteinuria (from 0,8±0,7 g/day to 0,08±0,6 g/day; <i>p</i>=0,04). At the same time no desiarable changes occurred in ESR (from 32,1±19,5 mm/hour to 17±26,5 mm/hour; <i>p</i>=0,1), GFR (from 62,2±42,9 mL/min to 54,2±31,9 mL/min; <i>p</i>=0,3). Although, second control biopsy&amp; histomorphology did not reveal amiloid depositions in duodenal mucous in 2 pts. <h3>Conclusions</h3> 12-mo Tocilizumab therapy resulted in target decrease of RA activity, accompanied by simultaneous decrease in SAA and 24-hour pronteinuria (although not all pts achieved the desired target levels), and complete disappearance of amiloid depositions in duodenal mucous in 2 pts. <h3>References</h3> Lane T, Gillmore JD, Wechalekar AD, ey al. Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature. Clin Exp Rheumatol. 2015 Nov-Dec;33(6 Suppl 94):S46–53. <h3>Disclosure of Interest</h3> None declared
AB0610 Platelet Factor 4 as A Biomarker in Korean Patients with Systemic Sclerosis
Authors: K.H. Jung, W. Park, S. Kwon, M.J. Lim
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Systemic sclerosis (SSc) is a complex multi-organ autoimmune disease with chronic and heterogeneous clinical manifestations. There is an unmet need for a new biomarker for early diagnosis and classification of SSc. Recent technical advancements have indicated several biomarkers for SSc; among these, platelet factor 4 (PF4), also known as CXCL4, was suggested by a large-cohort proteomic study <sup>1</sup>. PF4 is a chemokine released from activated platelets and is involved in coagulation, inflammation, and angiogenesis, which are influential in SSc pathogenesis. Therefore, PF4 may be an effective biomarker for SSc. <h3>Objectives</h3> To investigate the efficacy of PF4 as a biomarker for the diagnosis, activity and severity of patients with SSc. <h3>Methods</h3> Thirty-nine SSc patients (36 female and 3 male; mean age, 58.8±10.42 years; mean disease duration, 7.15±3.92 years; 11 diffuse cutaneous SSc cases and 28 limited cutaneous SSc cases) and 30 healthy controls (HC; 25 female and 5 male; mean age, 46.43±14.43 years) were enrolled. To estimate the circulating PF4 level, levels of platelet poor plasma (PPP) PF4 as well as serum PF4 were measured using an ELISA kit (R&amp;D, Minneapolis, USA). SSc patients were divided into 2 subgroups according to disease activity and based on the presence/absence of interstitial lung disease (ILD), pulmonary hypertension, digital ulcers, and autoantibodies (anti-centromere Ab and anti-Scl70 Ab). Differences between SSc and HC groups were compared by Student9s <i>t</i>-test, and the subgroups were compared using the Mann-Whitney test. Predictive values of serum PF4 and PPP PF4 for SSc diagnosis were evaluated by the area under the receiver operating characteristic curve (AUROC). <h3>Results</h3> Serum PF4 levels of SSc were lower than those of HC (SSc, 5143.3±1777.5 ng/mL; HC, 5927.4±1348.5 ng/mL; <i>p</i> =0.048) but no significant differences were observed PPP PF4 levels (SSc, 407.2±486.6 ng/mL; HC, 297.3±141.5 ng/mL; <i>p</i> =0.187) between SSc patients and controls. Moreover, no significant differences were observed between active and inactive SSc subgroups and between subgroups with/without ILD, pulmonary hypertension, digital ulcers, and autoantibodies. The AUROC for serum PF4 and PPP PF4 levels was 0.628 (0.497–0.76, cuff of value 3998.5 ng/mL) and 0.491 (0.367–0.65, cuff of value 511.1 ng/mL), respectively. <h3>Conclusions</h3> In Korean patients with SSc, both serum PF4 and PPP PF4 levels are not efficient biomarkers for SSc diagnosis and do not appear to be associated with clinical activity and severity. <h3>References</h3> van Roon JA, Tesselaar K, Radstake TR. Proteome-wide analysis and CXCL4 in systemic sclerosis. N Engl J Med. 2014;370(16):1563–4. <h3>Disclosure of Interest</h3> None declared